Kewaunee Scientific (US:KEQU)2020-12-11 20:21Sales Performance - Sales for the quarter were $39 million, a 1.8% decrease from $39.722 million in the comparable period of the prior year[63] - Domestic sales for the quarter were $28.772 million, down 8.9% from $31.584 million in the comparable period of the prior year[63] - International sales for the quarter were $10.228 million, up 25.7% from $8.138 million in the comparable period of the prior year[63] Financial Metrics - The gross profit margin for the three months ended October 31, 2020 was 16.4% of sales, compared to 15.9% in the prior year[66] - Operating expenses for the three months ended October 31, 2020 were $6.406 million, or 16.4% of sales, compared to $6.355 million, or 16.0% in the prior year[67] - Net loss was $180,000, or $0.07 per diluted share, for the three months ended October 31, 2020, compared to a net loss of $2.178 million, or $0.79 per diluted share, in the prior year[73] Order Backlog and Working Capital - The Company's order backlog was $96 million at October 31, 2020, compared to $92 million at October 31, 2019[65] - The Company had working capital of $28.53 million at October 31, 2020, compared to $27.171 million at April 30, 2020[75] Cash Flow - Cash used in operations was $516,000 during the six months ended October 31, 2020, primarily due to increases in receivables and inventory[76] COVID-19 Impact - The Company continues to monitor the impact of the COVID-19 pandemic, which remains uncertain and could materially affect business operations[77]